CYP 0.00% 22.0¢ cynata therapeutics limited

Screenshot(s) from Annual Report of 29 Aug 24, page-46

  1. 664 Posts.
    lightbulb Created with Sketch. 167
    No, I appreciate that the excerpts you posted are from CYP's corporate governance ann. So it is specific to CYP, but the issue of disclosure under placements and information asymmetry isn't. That CYP corporate governance statement ann is much like clinical trial result anns and an issue I have read you highlight previously - the ann is a summary/generalisation that glosses over some nuance and specifics. In this case it's a general statement of principles, but if you delve into the specifics it contains exceptions. That is a common issue, not just a CYP issue.

    CYP's full corporate governance disclosure is here: https://cynata.com/corporate-governance The Continuous Disclosure section alone is a 17 page pdf and notes the exception I posted from the Corporations Regulations in 2.2
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
(20min delay)
Last
22.0¢
Change
0.000(0.00%)
Mkt cap ! $39.74M
Open High Low Value Volume
22.5¢ 22.5¢ 22.0¢ $15.63K 71K

Buyers (Bids)

No. Vol. Price($)
2 20907 22.0¢
 

Sellers (Offers)

Price($) Vol. No.
23.0¢ 30000 2
View Market Depth
Last trade - 11.55am 11/11/2024 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.